glp-1 for inflammation drugs calm beyond diabetes and weight loss Stories like this are why

Obesity rates are rising

Stopping GLP-1 therapy typically leads to weight regain (50-70% within 12 months) and worsening glycaemic control in diabetes patients

In November 2023, the US pharma giant received FDA authorization for Zepbound under the trade name Mounjaro (both tirzepatide), and the drug produced $176 million in revenue over six weeks in 2023

There is no doctor named Anna Kowalska registered on the Medical Council of New Zealand's public register, and internet searches for her only turn up the same social media profile

An InBody scan tells you what they are made of and whether therapy is working in the right direction

Avoid heavy cream and fat bombs